Neogen
Specializing in development, license and supply of niche, complex and added-value generics products.
Financials
Estimates*
| EUR | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | 1.7m | 1.5m | - | 2.4m | - | - | - |
| % growth | 1 % | (10 %) | - | - | - | - | - |
| EBITDA | <1m | <1m | <1m | (1.2m) | <1m | - | - |
| % EBITDA margin | 30 % | 54 % | - | (48 %) | - | - | - |
| Profit | (<1m) | <1m | (<1m) | (2.0m) | <1m | <1m | 2.9m |
| % profit margin | (24 %) | 20 % | - | (83 %) | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
N/A | Growth Equity VC | ||
| Total Funding | - | ||
